{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:06:11Z","timestamp":1793419571732,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","award":["R25MH101075"],"award-info":[{"award-number":["R25MH101075"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40263-025-01199-z","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:31:01Z","timestamp":1752165061000},"page":"843-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action"],"prefix":"10.1007","volume":"39","author":[{"given":"Eric A.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-5679","authenticated-orcid":false,"given":"Carolina L.","family":"Haass-Koffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"1199_CR1","unstructured":"Global status report on alcohol and health and treatment of substance use disorders. Geneva: World Health Organization; 2024."},{"key":"1199_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.15585\/mmwr.mm7308a1","volume":"73","author":"MB Esser","year":"2024","unstructured":"Esser MB, Sherk A, Liu Y, Naimi TS. Deaths from excessive alcohol use\u2014United States, 2016\u20132021. MMWR Morb Mortal Wkly Rep. 2024;73:154\u201361.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1199_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","volume":"45","author":"LA Ray","year":"2019","unstructured":"Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45:124\u201340.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1176\/appi.ajp.20230488","volume":"180","author":"HR Kranzler","year":"2023","unstructured":"Kranzler HR. Overview of alcohol use disorder. Am J Psychiatry. 2023;180:565\u201372.","journal-title":"Am J Psychiatry"},{"key":"1199_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/alcalc\/agy089","volume":"54","author":"SP Byrne","year":"2019","unstructured":"Byrne SP, Haber P, Baillie A, Costa DSJ, Fogliati V, Morley K. Systematic reviews of mindfulness and acceptance and commitment therapy for alcohol use disorder: should we be using third wave therapies? Alcohol Alcohol. 2019;54:159\u201366.","journal-title":"Alcohol Alcohol"},{"key":"1199_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","volume":"27","author":"GM Keating","year":"2013","unstructured":"Keating GM. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs. 2013;27:761\u201372.","journal-title":"CNS Drugs"},{"key":"1199_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiat. 2021;78:922.","journal-title":"JAMA Psychiat"},{"key":"1199_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/02791072.1998.10399714","volume":"30","author":"M Mangini","year":"1998","unstructured":"Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs. 1998;30:381\u2013418.","journal-title":"J Psychoactive Drugs"},{"key":"1199_CR9","doi-asserted-by":"crossref","unstructured":"Cole JO, Katz MM. The psychotomimetic drugs: an overview. JAMA. 1964;187:758-61.","DOI":"10.1001\/jama.1964.03060230086021"},{"key":"1199_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131\u201381.","journal-title":"Pharmacol Ther"},{"key":"1199_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/02791072.1979.10472098","volume":"11","author":"CAP Ruck","year":"1979","unstructured":"Ruck CAP, Bigwood J, Staples D, Ott J, Wasson RG. Entheogens. J Psychedelic Drugs. 1979;11:145\u20136.","journal-title":"J Psychedelic Drugs"},{"key":"1199_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","volume":"66","author":"H Osmond","year":"1957","unstructured":"Osmond H. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci. 1957;66:418\u201334.","journal-title":"Ann N Y Acad Sci"},{"key":"1199_CR13","volume-title":"Realms of the human unconscious: observations from LSD research","author":"S Grof","year":"1975","unstructured":"Grof S. Realms of the human unconscious: observations from LSD research. New York: Viking Press; 1975."},{"key":"1199_CR14","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9:3897\u2013902.","journal-title":"NeuroReport"},{"key":"1199_CR15","doi-asserted-by":"crossref","unstructured":"Nichols DE. Psychedelics. Barker EL, editor. Pharmacol Rev. 2016;68:264\u2013355.","DOI":"10.1124\/pr.115.011478"},{"key":"1199_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","volume":"21","author":"TD McClure-Begley","year":"2022","unstructured":"McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022;21:463\u201373.","journal-title":"Nat Rev Drug Discov"},{"key":"1199_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1176\/appi.ajp.20230172","volume":"180","author":"BL Roth","year":"2023","unstructured":"Roth BL, Gumpper RH. Psychedelics as transformative therapeutics. Am J Psychiatry. 2023;180:340\u20137.","journal-title":"Am J Psychiatry"},{"key":"1199_CR18","doi-asserted-by":"crossref","unstructured":"Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, et al. Psychedelic\u2010assisted treatment for substance use disorder: a narrative systematic review. Addiction. 2025. Epub ahead of print. https:\/\/doi.org\/10.1111\/add.16762.","DOI":"10.1111\/add.16762"},{"key":"1199_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. 2022;79:953\u201362.","journal-title":"JAMA Psychiat"},{"key":"1199_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103149","volume":"82","author":"NM Rieser","year":"2025","unstructured":"Rieser NM, Bitar R, Halm S, Rossgoderer C, Gubser LP, Th\u00e9venaz M, et al. Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. eClinicalMedicine. 2025;82: 103149.","journal-title":"eClinicalMedicine"},{"key":"1199_CR21","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen P-\u00d8. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol (Oxf). 2012;26:994\u20131002.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"1199_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/03007995.2023.2296968","volume":"40","author":"D Sicignano","year":"2024","unstructured":"Sicignano D, Hernandez AV, Schiff B, Elmahy N, White CM. The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis. Curr Med Res Opin. 2024;40:293\u2013302.","journal-title":"Curr Med Res Opin"},{"key":"1199_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1176\/appi.psychotherapy.1966.20.3.415","volume":"20","author":"HA Abramson","year":"1966","unstructured":"Abramson HA. LSD in psychotherapy and alcoholism. Am J Psychother. 1966;20:415\u201338.","journal-title":"Am J Psychother"},{"key":"1199_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000468273","volume":"6","author":"FS Abuzzahab","year":"1971","unstructured":"Abuzzahab FS, Anderson BJ. A review of LSD treatment in alcoholism. Int Pharmacopsychiatry. 1971;6:223\u201335.","journal-title":"Int Pharmacopsychiatry"},{"key":"1199_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.15288\/qjsa.1958.19.406","volume":"19","author":"CM Smith","year":"1958","unstructured":"Smith CM. A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. Q J Stud Alcohol. 1958;19:406\u201317.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.15288\/qjsa.1959.20.577","volume":"20","author":"N Chwelos","year":"1959","unstructured":"Chwelos N, Blewett DB, Smith CM, Hoffer A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol. 1959;20:577\u201390.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR27","doi-asserted-by":"publisher","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","volume":"3","author":"I Hartogsohn","year":"2017","unstructured":"Hartogsohn I. Constructing drug effects: a history of set and setting. Drug Sci Policy Law. 2017;3:2050324516683325.","journal-title":"Drug Sci Policy Law."},{"key":"1199_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol (Oxf). 2008;22:603\u201320.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"1199_CR29","first-page":"331","volume":"23","author":"PO O\u2019reilly","year":"1962","unstructured":"O\u2019reilly PO, Reich G. Lysergic acid and the alcoholic. Dis Nerv Syst. 1962;23:331\u20134.","journal-title":"Dis Nerv Syst"},{"key":"1199_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/070674376400900311","volume":"9","author":"PO O\u2019Reilly","year":"1964","unstructured":"O\u2019Reilly PO, Funk A. LSD in chronic alcoholism. Can Psychiatr Assoc J. 1964;9:258\u201361.","journal-title":"Can Psychiatr Assoc J"},{"key":"1199_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00401542","volume":"12","author":"M Garg","year":"1968","unstructured":"Garg M, Holland HC. Consolidation and maze learning: the effects of post-trial injections of a depressant drug (pentobarbital sodium). Psychopharmacologia. 1968;12:127\u201332.","journal-title":"Psychopharmacologia"},{"key":"1199_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1037\/rev0000455","volume":"131","author":"MK Doss","year":"2024","unstructured":"Doss MK, Samaha J, Barrett FS, Griffiths RR, De Wit H, Gallo DA, et al. Unique effects of sedatives, dissociatives, psychedelics, stimulants, and cannabinoids on episodic memory: a review and reanalysis of acute drug effects on recollection, familiarity, and metamemory. Psychol Rev. 2024;131:523\u201362.","journal-title":"Psychol Rev"},{"key":"1199_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.15288\/qjsa.1961.22.034","volume":"22","author":"JR Maclean","year":"1961","unstructured":"Maclean JR, Macdonald DC, Byrne UP, Hubbard AM. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol. 1961;22:34\u201345.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.15288\/qjsa.1964.25.333","volume":"25","author":"RG Smart","year":"1964","unstructured":"Smart RG, Storm T. The efficacy of LSD in the treatment of alcoholism. Q J Stud Alcohol. 1964;25:333\u20138.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR35","doi-asserted-by":"publisher","first-page":"742","DOI":"10.15288\/qjsa.1964.25.742","volume":"25","author":"CM Smith","year":"1964","unstructured":"Smith CM. Exploratory and controlled studies of lysergide in the treatment of alcoholism. Q J Stud Alcohol. 1964;25:742\u20137.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.15288\/qjsa.1962.23.315","volume":"23","author":"SE Jensen","year":"1962","unstructured":"Jensen SE. A treatment program for alcoholics in a mental hospital. Q J Stud Alcohol. 1962;23:315\u201320.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/070674376300800305","volume":"8","author":"SE Jensen","year":"1963","unstructured":"Jensen SE, Ramsay R. Treatment of chronic alcoholism with lysergic acid diethylamide. Can Psychiatr Assoc J. 1963;8:182\u20138.","journal-title":"Can Psychiatr Assoc J"},{"key":"1199_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.15288\/qjsa.1967.28.295","volume":"28","author":"W Van Dusen","year":"1967","unstructured":"Van Dusen W, Wilson W, Miners W, Hook H. Treatment of alcoholism with lysergide. Q J Stud Alcohol. 1967;28:295\u2013304.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR39","first-page":"434","volume-title":"Use LSD psychother alcohol","author":"H Osmond","year":"1967","unstructured":"Osmond H, Albahary R, Cheek F, Sarett M. Some problems in the use of LSD 25 in the treatment of alcoholism. In: Abramson HA, editor. Use LSD psychother alcohol. Bobbs-Merrill; 1967. p. 434\u201357."},{"key":"1199_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","volume":"27","author":"RG Smart","year":"1966","unstructured":"Smart RG, Storm T, Baker EF, Solursh L. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol. 1966;27:469\u201382.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/h0022419","volume":"64","author":"LC Hartlage","year":"1965","unstructured":"Hartlage LC. Effects of chlorpromazine on learning. Psychol Bull. 1965;64:235\u201345.","journal-title":"Psychol Bull"},{"key":"1199_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1176\/ajp.126.1.59","volume":"126","author":"A Ludwig","year":"1969","unstructured":"Ludwig A, Levine J, Stark L, Lazar R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969;126:59\u201369.","journal-title":"Am J Psychiatry"},{"key":"1199_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","volume":"150","author":"WT Bowen","year":"1970","unstructured":"Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970;150:111\u20138.","journal-title":"J Nerv Ment Dis"},{"key":"1199_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, M\u00fcller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46:537\u201344.","journal-title":"Neuropsychopharmacology"},{"key":"1199_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1176\/ajp.126.4.481","volume":"126","author":"FG Johnson","year":"1969","unstructured":"Johnson FG. LSD in the treatment of alcoholism. Am J Psychiatry. 1969;126:481\u20137.","journal-title":"Am J Psychiatry"},{"key":"1199_CR46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","volume":"125","author":"LE Hollister","year":"1969","unstructured":"Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry. 1969;125:1352\u20137.","journal-title":"Am J Psychiatry"},{"key":"1199_CR47","doi-asserted-by":"publisher","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","volume":"31","author":"M Tomsovic","year":"1970","unstructured":"Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation. Q J Stud Alcohol. 1970;31:932\u201349.","journal-title":"Q J Stud Alcohol"},{"key":"1199_CR48","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","volume":"212","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN, Kurland A, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. J Am Med Assoc. 1970;212:1856.","journal-title":"J Am Med Assoc"},{"key":"1199_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0028-1094301","volume":"4","author":"A Kurland","year":"1971","unstructured":"Kurland A, Savage C, Pahnke WN, Grof S, Olsson JE. LSD in the treatment of alcoholics. Pharmacopsychiatry. 1971;4:83\u201394.","journal-title":"Pharmacopsychiatry"},{"key":"1199_CR50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","volume":"235","author":"KR Bonson","year":"2018","unstructured":"Bonson KR. Regulation of human research with LSD in the United States (1949\u20131987). Psychopharmacology. 2018;235:591\u2013604.","journal-title":"Psychopharmacology"},{"key":"1199_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ. Dose-response study of N, N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994;51:85.","journal-title":"Arch Gen Psychiatry"},{"key":"1199_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ. Dose-response study of N, N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51:98.","journal-title":"Arch Gen Psychiatry"},{"key":"1199_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268\u201383.","journal-title":"Psychopharmacology"},{"key":"1199_CR54","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol (Oxf). 2008;22:621\u201332.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"1199_CR55","unstructured":"Pahnke WN. Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness: A thesis [PhD Thesis]. Harvard University; 1963."},{"key":"1199_CR56","first-page":"1","volume":"23","author":"R Doblin","year":"1991","unstructured":"Doblin R. Pahnke\u2019s \u201cGood Friday experiment\u201d: a long-term follow-up and methodological critique. J Transpers Psychol. 1991;23:1\u201328.","journal-title":"J Transpers Psychol"},{"key":"1199_CR57","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735\u201340.","journal-title":"J Clin Psychiatry"},{"key":"1199_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00005053-199602000-00004","volume":"184","author":"CS Grob","year":"1996","unstructured":"Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996;184:86\u201394.","journal-title":"J Nerv Ment Dis"},{"key":"1199_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/02791072.2005.10399794","volume":"37","author":"E Doering-Silveira","year":"2005","unstructured":"Doering-Silveira E, Grob CS, De Rios MD, Lopez E, Alonso LK, Tacla C, et al. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs. 2005;37:141\u20134.","journal-title":"J Psychoactive Drugs"},{"key":"1199_CR60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","volume":"111","author":"JM F\u00e1bregas","year":"2010","unstructured":"F\u00e1bregas JM, Gonz\u00e1lez D, Fondevila S, Cutchet M, Fern\u00e1ndez X, Barbosa PCR, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend. 2010;111:257\u201361.","journal-title":"Drug Alcohol Depend"},{"key":"1199_CR61","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fpsyt.2018.00136","volume":"9","author":"PCR Barbosa","year":"2018","unstructured":"Barbosa PCR, T\u00f3foli LF, Bogenschutz MP, Hoy R, Berro LF, Marinho EAV, et al. Assessment of alcohol and tobacco use disorders among religious users of ayahuasca. Front Psychiatry. 2018;9:136.","journal-title":"Front Psychiatry."},{"key":"1199_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.comppsych.2016.09.003","volume":"71","author":"PCR Barbosa","year":"2016","unstructured":"Barbosa PCR, Strassman RJ, Da Silveira DX, Areco K, Hoy R, Pommy J, et al. Psychological and neuropsychological assessment of regular hoasca users. Compr Psychiatry. 2016;71:95\u2013105.","journal-title":"Compr Psychiatry"},{"key":"1199_CR63","doi-asserted-by":"publisher","first-page":"15201","DOI":"10.1038\/s41598-017-14700-6","volume":"7","author":"W Lawn","year":"2017","unstructured":"Lawn W, Hallak JE, Crippa JA, Dos Santos R, Porffy L, Barratt MJ, et al. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. Sci Rep. 2017;7:15201.","journal-title":"Sci Rep"},{"key":"1199_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/15733998113099990003","volume":"6","author":"G Thomas","year":"2013","unstructured":"Thomas G, Lucas P, Capler N, Tupper K, Martin G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev. 2013;6:30\u201342.","journal-title":"Curr Drug Abuse Rev"},{"key":"1199_CR65","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/02791072.2019.1607956","volume":"51","author":"I Berlowitz","year":"2019","unstructured":"Berlowitz I, Walt H, Ghasarian C, Mendive F, Martin-Soelch C. Short-term treatment effects of a substance use disorder therapy involving traditional Amazonian medicine. J Psychoactive Drugs. 2019;51:323\u201334.","journal-title":"J Psychoactive Drugs"},{"key":"1199_CR66","doi-asserted-by":"publisher","first-page":"607","DOI":"10.15288\/jsad.23-00005","volume":"85","author":"B Rush","year":"2024","unstructured":"Rush B, Marcus O, Garc\u00eda S, Loizaga-Velder A, Spitalier A, Mendive F. Ayahuasca treatment outcome project (ATOP): one-year results from Takiwasi Center and implications for psychedelic science. J Stud Alcohol Drugs. 2024;85:607\u201318.","journal-title":"J Stud Alcohol Drugs"},{"key":"1199_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884703","volume":"13","author":"D Perkins","year":"2022","unstructured":"Perkins D, Pagni BA, Sarris J, Barbosa PCR, Chenhall R. Changes in mental health, wellbeing and personality following ayahuasca consumption: results of a naturalistic longitudinal study. Front Pharmacol. 2022;13: 884703.","journal-title":"Front Pharmacol"},{"key":"1199_CR68","doi-asserted-by":"crossref","unstructured":"Pagni BA, Halman A, Sarris J, Chenhall R, Bogenschutz MP, Perkins D. Long-term mental health and wellbeing outcomes associated with naturalistic ayahuasca consumption. J Psychoactive Drugs. 2025;1\u201311. Epub ahead of print. DOI: 10.1080\/02791072.2025.2465800","DOI":"10.1080\/02791072.2025.2465800"},{"key":"1199_CR69","doi-asserted-by":"crossref","unstructured":"Rodrigues LS, Reis JAS, Rossi GN, Guerra LTL, Maekawa RM, De Lima Os\u00f3rio F, et al. Effects of a single dose of ayahuasca in college students with harmful alcohol use: a single-blind, feasibility, proof-of-concept trial. J Clin Psychopharmacol. 2024; 44(4):402-06.","DOI":"10.1097\/JCP.0000000000001872"},{"key":"1199_CR70","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol (Oxf). 2015;29:289\u201399.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"1199_CR71","doi-asserted-by":"publisher","first-page":"1215972","DOI":"10.3389\/fpsyt.2023.1215972","volume":"14","author":"KG Heinzerling","year":"2023","unstructured":"Heinzerling KG, Sergi K, Linton M, Rich R, Youssef B, Bentancourt I, et al. Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. Front Psychiatry. 2023;14:1215972.","journal-title":"Front Psychiatry."},{"key":"1199_CR72","doi-asserted-by":"crossref","unstructured":"Barstowe A, Kajonius PJ. Masking influences: a systematic review of placebo control and masking in psychedelic studies. J Psychoactive Drugs. 2024;1\u201311.","DOI":"10.1080\/02791072.2024.2424272"},{"key":"1199_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf023","volume":"28","author":"JS Aday","year":"2025","unstructured":"Aday JS, Simonsson O, Schindler EAD, D\u2019Souza DC. Addressing blinding in classic psychedelic studies with innovative active placebos. Int J Neuropsychopharmacol. 2025;28: pyaf023.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1199_CR74","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14:1133\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1199_CR75","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41591-021-01524-1","volume":"27","author":"MJ Burke","year":"2021","unstructured":"Burke MJ, Blumberger DM. Caution at psychiatry\u2019s psychedelic frontier. Nat Med. 2021;27:1687\u20138.","journal-title":"Nat Med"},{"key":"1199_CR76","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/17512433.2021.1951473","volume":"14","author":"EE Schenberg","year":"2021","unstructured":"Schenberg EE. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14:1317\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1199_CR77","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","volume":"239","author":"JS Aday","year":"2022","unstructured":"Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239:1989\u20132010.","journal-title":"Psychopharmacology"},{"key":"1199_CR78","first-page":"24com15504","volume":"85","author":"JF Rosenbaum","year":"2024","unstructured":"Rosenbaum JF. Functional unblinding in pivotal studies and the future of psychedelic medicine. J Clin Psychiatry. 2024;85:24com15504.","journal-title":"J Clin Psychiatry"},{"key":"1199_CR79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41583-023-00778-7","volume":"25","author":"LN Ross","year":"2024","unstructured":"Ross LN, Bassett DS. Causation in neuroscience: keeping mechanism meaningful. Nat Rev Neurosci. 2024;25:81\u201390.","journal-title":"Nat Rev Neurosci"},{"key":"1199_CR80","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","volume":"277","author":"AL Halberstadt","year":"2015","unstructured":"Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. 2015;277:99\u2013120.","journal-title":"Behav Brain Res"},{"key":"1199_CR81","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700\u20136.","journal-title":"Science"},{"key":"1199_CR82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118: e2022489118.","journal-title":"Proc Natl Acad Sci"},{"key":"1199_CR83","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"1199_CR84","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14:8221.","journal-title":"Nat Commun"},{"key":"1199_CR85","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535-2544.e4.","journal-title":"Neuron"},{"key":"1199_CR86","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41386-023-01572-w","volume":"48","author":"SJ Jefferson","year":"2023","unstructured":"Jefferson SJ, Gregg I, Dibbs M, Liao C, Wu H, Davoudian PA, et al. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology. 2023;48:1257\u201366.","journal-title":"Neuropsychopharmacology"},{"key":"1199_CR87","doi-asserted-by":"crossref","unstructured":"Liao C, Dua AN, Wojtasiewicz C, Liston C, Kwan AC. Structural neural plasticity evoked by rapid-acting antidepressant interventions. Nat Rev Neurosci. 2024.","DOI":"10.1038\/s41583-024-00876-0"},{"key":"1199_CR88","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","volume":"618","author":"R Nardou","year":"2023","unstructured":"Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, De Deus JL, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618:790\u20138.","journal-title":"Nature"},{"key":"1199_CR89","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci. 2012;109:2138\u201343.","journal-title":"Proc Natl Acad Sci"},{"key":"1199_CR90","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci. 2016;113:4853\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"1199_CR91","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082","volume":"7","author":"KH Preller","year":"2018","unstructured":"Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, St\u00e4mpfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7: e35082.","journal-title":"Elife"},{"key":"1199_CR92","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, St\u00e4mpfli P, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88:197\u2013207.","journal-title":"Biol Psychiatry"},{"key":"1199_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118143","volume":"10","author":"F Palhano-Fontes","year":"2015","unstructured":"Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JAS, Hallak JEC, et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. Hu D, editor. PLOS\u00a0One. 2015;10: e0118143.","journal-title":"PLOS\u00a0One."},{"key":"1199_CR94","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol. 2016;26:1043\u201350.","journal-title":"Curr Biol"},{"key":"1199_CR95","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","volume":"632","author":"JS Siegel","year":"2024","unstructured":"Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, et al. Psilocybin desynchronizes the human brain. Nature. 2024;632:131\u20138.","journal-title":"Nature"},{"key":"1199_CR96","doi-asserted-by":"crossref","unstructured":"Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20, pages 1-22. DOI: 10.3389\/fnhum.2014.00020.","DOI":"10.3389\/fnhum.2014.00020"},{"key":"1199_CR97","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2466\/pr0.1966.19.1.211","volume":"19","author":"WW Harman","year":"1966","unstructured":"Harman WW, McKim RH, Mogar RE, Fadiman J, Stolaroff MJ. Psychedelic agents in creative problem-solving: a pilot study. Psychol Rep. 1966;19:211\u201327.","journal-title":"Psychol Rep"},{"key":"1199_CR98","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/02698811211069113","volume":"36","author":"I Wie\u00dfner","year":"2022","unstructured":"Wie\u00dfner I, Falchi M, Maia LO, Daldegan-Bueno D, Palhano-Fontes F, Mason NL, et al. LSD and creativity: increased novelty and symbolic thinking, decreased utility and convergent thinking. J Psychopharmacol (Oxf). 2022;36:348\u201359.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"1199_CR99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/B978-0-12-816400-6.00006-7","volume-title":"Altered states of consciousness and creativity. Creat Wander Mind","author":"L Prochazkova","year":"2020","unstructured":"Prochazkova L, Hommel B. Altered states of consciousness and creativity. Creat Wander Mind. Elsevier; 2020. p. 121\u201358."},{"key":"1199_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109398","volume":"226","author":"RL Carhart-Harris","year":"2023","unstructured":"Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, et al. Canalization and plasticity in psychopathology. Neuropharmacology. 2023;226: 109398.","journal-title":"Neuropharmacology"},{"key":"1199_CR101","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1017\/S0033291719002393","volume":"50","author":"T Pokorny","year":"2020","unstructured":"Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med. 2020;50:2255\u201364.","journal-title":"Psychol Med"},{"key":"1199_CR102","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.neuron.2022.12.031","volume":"111","author":"C Sayal\u0131","year":"2023","unstructured":"Sayal\u0131 C, Barrett FS. The costs and benefits of psychedelics on cognition and mood. Neuron. 2023;111:614\u201330.","journal-title":"Neuron"},{"key":"1199_CR103","doi-asserted-by":"publisher","first-page":"14782","DOI":"10.1038\/s41598-024-65391-9","volume":"14","author":"LA Basedow","year":"2024","unstructured":"Basedow LA, Maji\u0107 T, Hafiz NJ, Algharably EAE, Kreutz R, Riemer TG. Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA\u2014a systematic review and meta-analysis. Sci Rep. 2024;14:14782.","journal-title":"Sci Rep"},{"key":"1199_CR104","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/brain\/awab406","volume":"145","author":"MK Doss","year":"2022","unstructured":"Doss MK, Madden MB, Gaddis A, Nebel MB, Griffiths RR, Mathur BN, et al. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain J Neurol. 2022;145:441\u201356.","journal-title":"Brain J Neurol."},{"key":"1199_CR105","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1126\/science.1192788","volume":"331","author":"JB Tenenbaum","year":"2011","unstructured":"Tenenbaum JB, Kemp C, Griffiths TL, Goodman ND. How to grow a mind: statistics, structure, and abstraction. Science. 2011;331:1279\u201385.","journal-title":"Science"},{"key":"1199_CR106","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Barker EL, editor. Pharmacol Rev. 2019;71:316\u201344.","journal-title":"Pharmacol Rev"},{"key":"1199_CR107","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00213-022-06153-1","volume":"239","author":"HT McGovern","year":"2022","unstructured":"McGovern HT, Leptourgos P, Hutchinson BT, Corlett PR. Do psychedelics change beliefs? Psychopharmacology. 2022;239:1809\u201321.","journal-title":"Psychopharmacology"},{"key":"1199_CR108","doi-asserted-by":"publisher","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","volume":"3","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 2001;3:265\u201379.","journal-title":"Dialogues Clin Neurosci"},{"key":"1199_CR109","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","volume":"56","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull. 2001;56:495\u2013507.","journal-title":"Brain Res Bull"},{"key":"1199_CR110","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1073\/pnas.1815129116","volume":"116","author":"KH Preller","year":"2019","unstructured":"Preller KH, Razi A, Zeidman P, St\u00e4mpfli P, Friston KJ, Vollenweider FX. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc Natl Acad Sci U S A. 2019;116:2743\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1199_CR111","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1038\/s41598-024-52967-8","volume":"14","author":"BA Pagni","year":"2024","unstructured":"Pagni BA, Petridis PD, Podrebarac SK, Grinband J, Claus ED, Bogenschutz MP. Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study. Sci Rep. 2024;14:3159.","journal-title":"Sci Rep"},{"key":"1199_CR112","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1176\/appi.ajp.20230887","volume":"182","author":"BA Pagni","year":"2025","unstructured":"Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, et al. Multidimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder: results from a double-blind, placebo-controlled clinical trial. Am J Psychiatry. 2025;182:114\u201325.","journal-title":"Am J Psychiatry"},{"key":"1199_CR113","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1017\/S0033291723001514","volume":"54","author":"B Weiss","year":"2024","unstructured":"Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, et al. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychol Med. 2024;54:178\u201392.","journal-title":"Psychol Med"},{"key":"1199_CR114","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4414\/sanp.2012.00110","volume":"163","author":"OF Kernberg","year":"2012","unstructured":"Kernberg OF. Overview and critique of the classification of personality disorders proposed for DSM-V. Schweiz Arch F\u00fcr Neurol Psychiatr. 2012;163:234\u20138.","journal-title":"Schweiz Arch F\u00fcr Neurol Psychiatr."},{"key":"1199_CR115","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archpsyc.1959.03590010063008","volume":"1","author":"KS Ditman","year":"1959","unstructured":"Ditman KS, Whittlesey JRB. Comparison of the LSD-25 experience and delirium tremens. Arch Gen Psychiatry. 1959;1:47.","journal-title":"Arch Gen Psychiatry"},{"key":"1199_CR116","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF01532646","volume":"5","author":"WN Pahnke","year":"1966","unstructured":"Pahnke WN, Richards WA. Implications of LSD and experimental mysticism. J Relig Health. 1966;5:175\u2013208.","journal-title":"J Relig Health"},{"key":"1199_CR117","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8:974.","journal-title":"Front Pharmacol"},{"key":"1199_CR118","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:568\u201372.","journal-title":"ACS Pharmacol Transl Sci."},{"key":"1199_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.917199","volume":"13","author":"K Ko","year":"2022","unstructured":"Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Front Psychiatry. 2022;13: 917199.","journal-title":"Front Psychiatry."},{"key":"1199_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106086","volume":"172","author":"B Romeo","year":"2025","unstructured":"Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Bezo A, et al. The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2025;172: 106086.","journal-title":"Neurosci Biobehav Rev"},{"key":"1199_CR121","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamapsychiatry.2023.1554","volume":"80","author":"R Palitsky","year":"2023","unstructured":"Palitsky R, Kaplan DM, Peacock C, Zarrabi AJ, Maples-Keller JL, Grant GH, et al. Importance of integrating spiritual, existential, religious, and theological components in psychedelic-assisted therapies. JAMA Psychiat. 2023;80:743.","journal-title":"JAMA Psychiat"},{"key":"1199_CR122","doi-asserted-by":"publisher","first-page":"1020505","DOI":"10.3389\/fpsyt.2022.1020505","volume":"13","author":"T Passie","year":"2022","unstructured":"Passie T, Guss J, Kr\u00e4henmann R. Lower-dose psycholytic therapy\u2014a neglected approach. Front Psychiatry. 2022;13:1020505.","journal-title":"Front Psychiatry."},{"key":"1199_CR123","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 1986;18:305\u201313.","journal-title":"J Psychoactive Drugs"},{"key":"1199_CR124","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med"},{"key":"1199_CR125","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, Van Der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380.","journal-title":"Nat Med"},{"key":"1199_CR126","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0022167817706884","volume":"57","author":"AB Belser","year":"2017","unstructured":"Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, et al. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol. 2017;57:354\u201388.","journal-title":"J Humanist Psychol"},{"key":"1199_CR127","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol. 2017;57:520\u201364.","journal-title":"J Humanist Psychol"},{"key":"1199_CR128","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1037\/adb0000935","volume":"38","author":"G Agin-Liebes","year":"2024","unstructured":"Agin-Liebes G, Nielson EM, Zingman M, Kim K, Haas A, Owens LT, et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: an interpretive phenomenological analysis. Psychol Addict Behav. 2024;38:101\u201313.","journal-title":"Psychol Addict Behav"},{"key":"1199_CR129","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2021","unstructured":"Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:563\u20137.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1199_CR130","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14740338.2023.2253144","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS. Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents. Expert Opin Drug Saf. 2023;22:885\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"1199_CR131","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/02791072.2021.1986243","volume":"53","author":"JE Swan","year":"2021","unstructured":"Swan JE, Aldridge A, Joseph V, Tucker JA, Witkiewitz K. Individual and community social determinants of health and recovery from alcohol use disorder three years following treatment. J Psychoactive Drugs. 2021;53:394\u2013403.","journal-title":"J Psychoactive Drugs"},{"key":"1199_CR132","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","volume":"79","author":"DB Yaden","year":"2022","unstructured":"Yaden DB, Potash JB, Griffiths RR. Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiat. 2022;79:943.","journal-title":"JAMA Psychiat"},{"key":"1199_CR133","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, M\u00fcller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638\u201346.","journal-title":"Neuropsychopharmacology"},{"key":"1199_CR134","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3389\/fpsyt.2019.00881","volume":"10","author":"KH Preller","year":"2019","unstructured":"Preller KH, Vollenweider FX. Modulation of social cognition via hallucinogens and \u201centactogens.\u201d Front Psychiatry. 2019;10:881.","journal-title":"Front Psychiatry"},{"key":"1199_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.623985","volume":"12","author":"H Kettner","year":"2021","unstructured":"Kettner H, Rosas FE, Timmermann C, K\u00e4rtner L, Carhart-Harris RL, Roseman L. Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Front Pharmacol. 2021;12: 623985.","journal-title":"Front Pharmacol"},{"key":"1199_CR136","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s44220-024-00302-5","volume":"2","author":"M Newson","year":"2024","unstructured":"Newson M, Haslam SA, Haslam C, Cruwys T, Roseman L. Social identity processes as a vehicle for therapeutic success in psychedelic treatment. Nat Ment Health. 2024;2:1010\u20137.","journal-title":"Nat Ment Health."},{"key":"1199_CR137","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","volume":"51","author":"A Trope","year":"2019","unstructured":"Trope A, Anderson BT, Hooker AR, Glick G, Stauffer C, Woolley JD. Psychedelic-assisted group therapy: a systematic review. J Psychoactive Drugs. 2019;51:174\u201388.","journal-title":"J Psychoactive Drugs"},{"key":"1199_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","volume":"27","author":"BT Anderson","year":"2020","unstructured":"Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27: 100538.","journal-title":"EClinicalMedicine."},{"key":"1199_CR139","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","volume":"66","author":"BR Lewis","year":"2023","unstructured":"Lewis BR, Garland EL, Byrne K, Durns T, Hendrick J, Beck A, et al. HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with cancer. J Pain Symptom Manage. 2023;66:258\u201369.","journal-title":"J Pain Symptom Manage"},{"key":"1199_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.863552","volume":"13","author":"P Oehen","year":"2022","unstructured":"Oehen P, Gasser P. Using a MDMA- and LSD-group therapy model in clinical practice in switzerland and highlighting the treatment of trauma-related disorders. Front Psychiatry. 2022;13: 863552.","journal-title":"Front Psychiatry."},{"key":"1199_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103380","volume":"98","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Berghella AP, Regier PS, Garcia-Romeu A, Johnson MW, Hendricks PS. Classic psychedelics in the treatment of substance use disorder: potential synergies with twelve-step programs. Int J Drug Policy. 2021;98: 103380.","journal-title":"Int J Drug Policy"},{"key":"1199_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.607529","volume":"12","author":"L Roseman","year":"2021","unstructured":"Roseman L, Ron Y, Saca A, Ginsberg N, Luan L, Karkabi N, et al. Relational processes in ayahuasca groups of Palestinians and Israelis. Front Pharmacol. 2021;12: 607529.","journal-title":"Front Pharmacol"},{"key":"1199_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.718934","volume":"12","author":"L Roseman","year":"2021","unstructured":"Roseman L, Karkabi N. On revelations and revolutions: drinking ayahuasca among Palestinians under Israeli occupation. Front Psychol. 2021;12: 718934.","journal-title":"Front Psychol"},{"key":"1199_CR144","volume-title":"Ayahuasca shamanism in the Amazon and beyond","year":"2014","unstructured":"Labate BC, Cavnar C, editors. Ayahuasca shamanism in the Amazon and beyond. New York: Oxford University Press; 2014."},{"key":"1199_CR145","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol (Oxf). 2022;36:258\u201372.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"1199_CR146","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s44161-025-00608-2","volume":"4","author":"A Nahlawi","year":"2025","unstructured":"Nahlawi A, Ptaszek LM, Ruskin JN. Cardiovascular effects and safety of classic psychedelics. Nat Cardiovasc Res. 2025;4:131\u201344.","journal-title":"Nat Cardiovasc Res."},{"key":"1199_CR147","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/14740338.2023.2248883","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS. Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. Expert Opin Drug Saf. 2023;22:881\u20133.","journal-title":"Expert Opin Drug Saf"},{"key":"1199_CR148","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos J-MS, Johnson MW, Griffiths RR. The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol (Oxf). 2016;30:1279\u201395.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"1199_CR149","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","volume":"326","author":"O Simonsson","year":"2023","unstructured":"Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord. 2023;326:105\u201310.","journal-title":"J Affect Disord"},{"key":"1199_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102997","volume":"87","author":"L Gashi","year":"2021","unstructured":"Gashi L, Sandberg S, Pedersen W. Making, \u201cbad trips\u201d good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy. 2021;87: 102997.","journal-title":"Int J Drug Policy"},{"key":"1199_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, Suseelan S, Murphy-Beiner A, McAlpine R, et al. Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS\u00a0One. 2023;18: e0293349.","journal-title":"PLoS\u00a0One"},{"key":"1199_CR152","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","volume":"232","author":"RL Carhart-Harris","year":"2015","unstructured":"Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ. LSD enhances suggestibility in healthy volunteers. Psychopharmacology. 2015;232:785\u201394.","journal-title":"Psychopharmacology"},{"key":"1199_CR153","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","volume":"7","author":"BT Anderson","year":"2020","unstructured":"Anderson BT, Danforth AL, Grob CS. Psychedelic medicine: safety and ethical concerns. Lancet Psychiatry. 2020;7:829\u201330.","journal-title":"Lancet Psychiatry"},{"key":"1199_CR154","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"S McNamee","year":"2023","unstructured":"McNamee S, Devenot N, Buisson M. Studying harms is key to improving psychedelic-assisted therapy\u2014participants call for changes to research landscape. JAMA Psychiat. 2023;80:411.","journal-title":"JAMA Psychiat"},{"key":"1199_CR155","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgae560","volume":"4","author":"K Zhou","year":"2025","unstructured":"Zhou K, De Wied D, Carhart-Harris RL, Kettner H. Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use. Fleming S, editor. PNAS Nexus. 2025;4: pgae560.","journal-title":"PNAS Nexus."},{"key":"1199_CR156","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1037\/h0088751","volume":"6","author":"R Metzner","year":"1969","unstructured":"Metzner R. A note on the treatment of LSD psychosis: a case report. Psychother Theory Res Pract. 1969;6:201\u20135.","journal-title":"Psychother Theory Res Pract"},{"key":"1199_CR157","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","volume":"130","author":"S Cohen","year":"1960","unstructured":"Cohen S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis. 1960;130:30\u201340.","journal-title":"J Nerv Ment Dis"},{"key":"1199_CR158","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.118.543.229","volume":"118","author":"N Malleson","year":"1971","unstructured":"Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry. 1971;118:229\u201330.","journal-title":"Br J Psychiatry"},{"key":"1199_CR159","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41380-024-02800-5","volume":"30","author":"M Sab\u00e9","year":"2025","unstructured":"Sab\u00e9 M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30:1223\u201355.","journal-title":"Mol Psychiatry"},{"key":"1199_CR160","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063972","volume":"8","author":"TS Krebs","year":"2013","unstructured":"Krebs TS, Johansen P-\u00d8. Psychedelics and mental health: a population study. Lu L, editor. PLoS\u00a0One. 2013;8: e63972.","journal-title":"PLoS\u00a0One"},{"key":"1199_CR161","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/jcm14051416","volume":"14","author":"S Meshkat","year":"2025","unstructured":"Meshkat S, Malik T, Zeifman R, Swainson J, Zhang Y, Burback L, et al. Psychedelics and suicide-related outcomes: a systematic review. J Clin Med. 2025;14:1416.","journal-title":"J Clin Med"},{"key":"1199_CR162","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"1199_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116381","volume":"345","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Sauer T, H\u00e4nny C, M\u00fchlhauser M, Lang UE. Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: a case report. Psychiatry Res. 2025;345: 116381.","journal-title":"Psychiatry Res"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01199-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:49:27Z","timestamp":1757224167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01199-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":163,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01199-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"4 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.A.M. is supported by NIMH R25MH101075 \u201cPromoting Research Training During Psychiatry Residency\u201d, PI: A. Tyrka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E.A.M., C.C., E.E., and R.M.S. declare no competing interests. C.L.H.-K. received mifepristone and placebo for another trial and travel support to present at the Corcept Therapeutics Scientific Conference (September 2022). She holds two patents for the development of negative allosteric modulators and one patent for the development of a compound for noradrenergic blockade; all are unrelated to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"E.A.M. conceptualized and wrote the initial draft of the manuscript. E.A.M., E.E., C.C., R.M.S., and C.L.H-K. wrote the manuscript. C.L.H-K. oversaw the project as PI. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}